Cargando…
Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia
Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy with poor clinical outcomes. To determine whether the expression of the long non-coding (lnc)RNA zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) is associated with clinical outcomes, its expression was analyzed i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507462/ https://www.ncbi.nlm.nih.gov/pubmed/31186703 http://dx.doi.org/10.3892/ol.2019.10149 |
_version_ | 1783417031132971008 |
---|---|
author | Shi, Xiaolan Li, Jiao Ma, Liang Wen, Lijun Wang, Qinrong Yao, Hong Ruan, Changgeng Wu, Depei Zhang, Xinyou Chen, Suning |
author_facet | Shi, Xiaolan Li, Jiao Ma, Liang Wen, Lijun Wang, Qinrong Yao, Hong Ruan, Changgeng Wu, Depei Zhang, Xinyou Chen, Suning |
author_sort | Shi, Xiaolan |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy with poor clinical outcomes. To determine whether the expression of the long non-coding (lnc)RNA zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) is associated with clinical outcomes, its expression was analyzed in a retrospective cohort of 62 AML and 10 non-malignant cases. The results revealed that the expression of ZEB2-AS1 lncRNA was notably high and closely associated with adverse clinical outcomes in AML cases compared with the non-malignant cases, based on either modified Medical Research Council or European Leukemia Net risk stratification systems. Univariate analyses indicated that patients with a higher expression of ZEB2-AS1 lncRNA had significantly shorter overall survival (OS) (P=0.036) and disease-free survival (DFS) rates (P=0.039) compared with patients with a lower expression of ZEB2-AS1 lncRNA. In addition, patients with a higher expression of ZEB2-AS1 lncRNA had a significant lower complete remission rate in response to induction by chemotherapy compared with patients with a lower expression of ZEB2-AS1 lncRNA (P=0.031). In cases with low levels of ZEB2-AS1 lncRNA, patients treated with allogenic hematopoietic stem cell transplantation had significantly longer OS and DFS rates compared with that of chemotherapy-treated patients (P=0.037 and P=0.049 respectively). Furthermore, the knockdown of ZEB2-AS1 lncRNA effectively inhibited AML cell invasion and migration, which was closely associated with the downregulation of ZEB2 and upregulation of E-cadherin expression. Collectively, although its independent prognostic value for survival was not rigorously determined, ZEB2-AS1 lncRNA may function as a candidate marker to improve conventional risk stratification systems and the evaluation of therapeutic responses for AML. |
format | Online Article Text |
id | pubmed-6507462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-65074622019-06-11 Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia Shi, Xiaolan Li, Jiao Ma, Liang Wen, Lijun Wang, Qinrong Yao, Hong Ruan, Changgeng Wu, Depei Zhang, Xinyou Chen, Suning Oncol Lett Articles Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy with poor clinical outcomes. To determine whether the expression of the long non-coding (lnc)RNA zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) is associated with clinical outcomes, its expression was analyzed in a retrospective cohort of 62 AML and 10 non-malignant cases. The results revealed that the expression of ZEB2-AS1 lncRNA was notably high and closely associated with adverse clinical outcomes in AML cases compared with the non-malignant cases, based on either modified Medical Research Council or European Leukemia Net risk stratification systems. Univariate analyses indicated that patients with a higher expression of ZEB2-AS1 lncRNA had significantly shorter overall survival (OS) (P=0.036) and disease-free survival (DFS) rates (P=0.039) compared with patients with a lower expression of ZEB2-AS1 lncRNA. In addition, patients with a higher expression of ZEB2-AS1 lncRNA had a significant lower complete remission rate in response to induction by chemotherapy compared with patients with a lower expression of ZEB2-AS1 lncRNA (P=0.031). In cases with low levels of ZEB2-AS1 lncRNA, patients treated with allogenic hematopoietic stem cell transplantation had significantly longer OS and DFS rates compared with that of chemotherapy-treated patients (P=0.037 and P=0.049 respectively). Furthermore, the knockdown of ZEB2-AS1 lncRNA effectively inhibited AML cell invasion and migration, which was closely associated with the downregulation of ZEB2 and upregulation of E-cadherin expression. Collectively, although its independent prognostic value for survival was not rigorously determined, ZEB2-AS1 lncRNA may function as a candidate marker to improve conventional risk stratification systems and the evaluation of therapeutic responses for AML. D.A. Spandidos 2019-06 2019-03-15 /pmc/articles/PMC6507462/ /pubmed/31186703 http://dx.doi.org/10.3892/ol.2019.10149 Text en Copyright: © Shi et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Shi, Xiaolan Li, Jiao Ma, Liang Wen, Lijun Wang, Qinrong Yao, Hong Ruan, Changgeng Wu, Depei Zhang, Xinyou Chen, Suning Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title_full | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title_fullStr | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title_full_unstemmed | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title_short | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
title_sort | overexpression of zeb2-as1 lncrna is associated with poor clinical outcomes in acute myeloid leukemia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507462/ https://www.ncbi.nlm.nih.gov/pubmed/31186703 http://dx.doi.org/10.3892/ol.2019.10149 |
work_keys_str_mv | AT shixiaolan overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT lijiao overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT maliang overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT wenlijun overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT wangqinrong overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT yaohong overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT ruanchanggeng overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT wudepei overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT zhangxinyou overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia AT chensuning overexpressionofzeb2as1lncrnaisassociatedwithpoorclinicaloutcomesinacutemyeloidleukemia |